IRIS
TOCCHETTI, CARLO GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.821
EU - Europa 2.093
AS - Asia 1.364
AF - Africa 126
SA - Sud America 19
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.752
IT - Italia 1.103
SG - Singapore 671
CN - Cina 493
NL - Olanda 215
FI - Finlandia 148
DE - Germania 116
UA - Ucraina 101
SE - Svezia 98
IE - Irlanda 93
VN - Vietnam 87
CI - Costa d'Avorio 85
CA - Canada 65
FR - Francia 41
IN - India 39
GB - Regno Unito 33
ES - Italia 25
PT - Portogallo 22
JP - Giappone 18
BE - Belgio 17
BG - Bulgaria 15
NG - Nigeria 12
EG - Egitto 11
TR - Turchia 11
HK - Hong Kong 10
CO - Colombia 9
RU - Federazione Russa 9
SK - Slovacchia (Repubblica Slovacca) 9
PL - Polonia 8
GR - Grecia 6
KR - Corea 5
AR - Argentina 4
AT - Austria 4
ET - Etiopia 4
GE - Georgia 4
HR - Croazia 4
IR - Iran 4
LT - Lituania 4
MA - Marocco 4
MX - Messico 4
PH - Filippine 4
PK - Pakistan 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
KE - Kenya 3
LV - Lettonia 3
MK - Macedonia 3
TN - Tunisia 3
TW - Taiwan 3
AU - Australia 2
BJ - Benin 2
CH - Svizzera 2
CL - Cile 2
CY - Cipro 2
EU - Europa 2
IL - Israele 2
NO - Norvegia 2
PE - Perù 2
RO - Romania 2
AM - Armenia 1
BD - Bangladesh 1
BR - Brasile 1
DK - Danimarca 1
DZ - Algeria 1
LI - Liechtenstein 1
NZ - Nuova Zelanda 1
OM - Oman 1
SI - Slovenia 1
TH - Thailandia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 7.428
Salva come PNG Salva come JPEG
Città #
Chandler 779
Singapore 548
Ashburn 263
Amsterdam 200
Millbury 187
Naples 187
Nanjing 152
Boston 148
Des Moines 136
Princeton 131
Santa Clara 131
Wilmington 109
Jacksonville 100
Dong Ket 86
Lawrence 86
Beijing 84
Napoli 70
Ottawa 55
Woodbridge 54
Rome 43
Hebei 40
Nanchang 39
Milan 37
Shenyang 33
Pune 31
Lappeenranta 27
Houston 26
Seattle 26
Norwalk 23
Palermo 22
Washington 21
Fairfield 20
Dearborn 19
Jiaxing 19
Boardman 16
Changsha 16
Council Bluffs 16
Dublin 16
Redwood City 16
Tianjin 16
Bologna 15
Dallas 15
Guangzhou 15
Sofia 15
Caserta 14
Hangzhou 13
Turin 13
Chengdu 12
Rho 12
Augusta 11
Madrid 11
Menlo Park 11
Munich 11
Brescia 10
Fisciano 10
Kronberg 10
Los Angeles 10
Montijo 10
Perugia 10
Bari 9
Battipaglia 9
Kosice 9
Maasmechelen 9
Ariano Irpino 8
Helsinki 8
Manfredonia 8
Marcianise 8
Solofra 8
Cambridge 7
Catania 7
Hong Kong 7
Shenzhen 7
Bogotá 6
Florence 6
Foggia 6
Kunming 6
Shanghai 6
Trieste 6
Cicciano 5
Leawood 5
Mountain View 5
Stockholm 5
Warsaw 5
Acerra 4
Addis Ababa 4
Ann Arbor 4
Bergamo 4
Cairo 4
Cologne 4
Düsseldorf 4
Fremont 4
Grottolella 4
Jinan 4
Locorotondo 4
Oeiras 4
Paris 4
Pescara 4
Piemonte 4
Pisa 4
Portici 4
Totale 4.489
Salva come PNG Salva come JPEG
Nome #
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice 537
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 88
Aldose Reductase Inhibition or Activation of Transketolase Offset Adverse Metabolic Remodeling Improving Function in Type 2 Diabetes Myocytes Exposed to Hyperglycemia 71
Antineoplastic drug-induced cardiotoxicity: A redox perspective 67
Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed 64
Cardiac sympathetic dysfunction in pulmonary arterial hypertension: Lesson from left-sided heart failure 63
Late INa Inhibition with Ranolazine Blunts Doxorubicin- Induced Cardiac Dysfunction and Remodeling in Mice 62
Doxorubicin-induced cardiotoxicity in mice is blunted by late sodium current inhibition with ranolazine, with improvement in heart function, fibrosis and apoptosis. 61
Palmitate improves basal and beta-stimulated left ventricle function in diabetic mouse hearts 60
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 59
Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities 59
ANTHRACYCLINE INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS, APOPTOSIS 57
Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. 57
Utility of 2D-speckle tracking echocardiography in early identification of left ventricular dysfunction in antineoplastic therapy-induced cardiotoxicity. 56
Severe Aortic Valve Regurgitation in Relapsing Polychondritis 56
Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function 56
Meccanismi molecolari della cardiotossicità indotta da antracicline e radioterapia 55
Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients 54
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue 54
Targeting fibrosis in the failing heart with nanoparticles. 54
Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction. 52
Effect of inhibition of ErbB2-tyrosine kinase domain with lapatinib on cardiac dysfunction compared to the antibody trastuzumab in mice 51
Palmitate Improves Redox Balance and Enhances Contractility While Offsetting Adverse Effects of Hyperglycemia in the Diabetic Cardiomyocyte 51
Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship? 51
The anticancer mTOR-inhibitor temsirolimus induces cardiac dysfunction in mice 50
Palmitate re-directs glucose utilization in type 2 diabetic hearts, improving function: a metabolomic/fluxomic study. 50
Dobutamine stress echocardiography in hypertrophic cardiomyopathy 50
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 50
The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in the Beneficial Interplay Between Dietary Fiber and Cardiovascular Health 49
Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes 49
Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart 49
Cardiac overexpression of CK improves myocellular function in murine heart failure. 48
Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. 48
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial 48
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients 48
What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients 48
Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC 47
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond 47
Cardiotoxicity of immune checkpoint inhibitors 47
Myocardial collagen turnover in hypertrophic cardiomyopathy 46
Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula? 46
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 46
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 46
The Tyrosine Kinase ErbB2 Inhibitor Lapatinib and the Anti- ErbB2 Antibody Trastuzumab Depress Cardiac Function Without Inducing Left Ventricular Dilation in Mice 45
Nitroxyl: A positive inotrope enhancing SR CA(2+) cycling in isolated myocytes 45
Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects 45
Biomarkers in sarcopenia: A multifactorial approach. 45
Adapted recreational football Small Sided Games improves cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes: results from a pilot study 45
Physical vs. multidimensional frailty in older adults with and without heart failure 45
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart 45
Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis 44
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 43
Prognostic Significance of Left Atrial Volume Dilatation in Patients with Hypertrophic Cardiomyopathy 43
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth 43
Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: comparison with normal subjects 42
The innate immune system in chronic cardiomyopathy: A European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC 42
Non-coding RNAs - Update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart 42
Tetrahydrobiopterin (BH4) reverses established heart failure normalizing calcium cycling at the cardiomyocytes level 41
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications 41
Direct oral anticoagulants across the heart failure spectrum: the precision medicine era 40
Time-weighted lactate as a predictor of adverse outcome in acute heart failure 40
Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs 39
DECREASED GLOBAL LONGITUDINAL STRAIN WITH MYOCARDITIS FROM IMMUNE CHECKPOINT INHIBITORS AND OCCURRENCE OF MAJOR ADVERSE CARDIAC EVENTS 39
An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology 38
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology 38
Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology 38
Editorial: Novel Therapeutic Strategies for the Treatment of Chronic Diseases 38
Oxidative stress in anticancer therapies-related cardiac dysfunction 38
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF 38
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 38
'Circulating' RNA-based therapies in Cardio-Oncology 37
Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases 37
The continuous heart failure spectrum: moving beyond an ejection fraction classification 37
Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens 37
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications 37
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology 36
PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus 36
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs 36
Bidirectional cross-regulation between ErbB2 and β-adrenergic signaling pathways 36
Metabolic Aspects of Anthracycline Cardiotoxicity 36
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 35
Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology 35
The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) 35
Functional importance of Insulin-like Growth Factor I receptor COOH-terminal region tyrosine phosphorylation sites. 34
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions—A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology 34
Pathophysiology of anthracycline cardiotoxicity 34
Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models 34
Complex Roads from Genotype to Phenotype in Dilated Cardiomyopathy: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology 34
Common Mechanistic Pathways in Cancer and Heart Failure 34
Cardiovascular events and treatment of children with high risk medulloblastoma 34
Beta-blockers in pulmonary arterial hypertension: Time for a second thought? 34
Inhibition of cardiomyocytes late I-Na with ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo 33
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure 33
Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC) 33
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors 33
A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases 33
Le alterazioni elettrocardiografiche espressione di cardiotossicita’ (Electrocardiographic changes: expression of cardiotoxicity) 32
Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5 32
The activation of metabolites of nitric oxide synthase by metals is both redox and oxygen dependent: A new feature of nitrogen oxide signaling 32
Commentary on “Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fraction” 32
Totale 4.962
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.689
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.689
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020333 0 0 0 0 47 25 22 33 17 45 81 63
2020/2021625 26 57 42 39 48 65 52 31 46 60 63 96
2021/20221.132 31 4 15 21 30 32 42 62 101 100 190 504
2022/20232.192 251 122 84 176 273 209 58 258 381 240 105 35
2023/20241.527 47 190 230 115 89 216 72 184 29 48 213 94
2024/20251.032 352 438 40 62 140 0 0 0 0 0 0 0
Totale 7.937